Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
The CAR Macrophage-Mediated Trogocytosis Assay is a cutting-edge technique that enables scientists to study cell-to-cell interactions, particularly focusing on CAR macrophages. This assay provides invaluable insights into the cellular crosstalk that underlies the efficacy and safety of CAR-MA cell therapies, a promising approach for cancer and autoimmune disease treatment.
Trogocytosis, often described as "nibbling", is a cellular process where one cell takes small "bites" of a neighboring cell during direct contact. This process involves the rapid transfer of membrane fragments and their associated molecules between cells, representing a subtle form of cell-to-cell communication. Trogocytosis has been observed in various immune cells, including T cells, natural killer (NK) cells, dendritic cells (DC), macrophages, neutrophils, and basophils. Regardless of the cell type involved, a key requirement for trogocytosis is direct cell-to-cell contact, potentially involving the formation of an immune synapse. This process serves various important functions, including cell communication, activation, elimination of microbial pathogens, and control of cancer cells. However, trogocytosis can also have adverse effects, as seen in instances where it leads to fratricide of CAR-T cells, potentially allowing tumors to escape control.
Fig.1 Characteristics of phagocytosis vs. trogocytosis.1,3
In the bites assay, macrophages are capable of engulfing entire, viable cancer cells, but it's common for macrophage interactions with their targets to result in partial ingestion, where only a fragment of the target cell is taken in. In this process, CAR-MA and tumor cells are allowed to interact within a confined space for a specified duration, followed by dilution for imaging.
Through this method, we can visualize the trogocytosis process and quantify the proportion of CAR-MA cells that internalize one or more "bites" of the target cells. To determine whether trogocytosis has a significant impact on reducing the number of cancer cells, CAR-MA and tumor cells are incubated together, and the count of tumor cells is subsequently quantified using FACS.
Fig.2 CAR-P promotes trogocytosis.2,3
As a leading cell therapeutics development biotech, Creative Biolabs is proficient at performing bite assays. We also provide high-quality Bead engulfment assay and Eating assay. Please keep in mind that in addition to our standard contract assay services, we also offer customization options to meet the unique requirements of different research projects.
Please contact us for more information about the different assays or services that are available to support your programs.
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
